FrancophonIA/ELRC3.0 huggingface dataset:
English: • To warn women of childbearing age to not become pregnant because deferiprone may seriously harm the unborn baby
Estonian: • hoiatada viljastumisvõimelisi naisi rasestumise eest, sest deferiproon võib loodet raskelt kahjustada
English: Data from the published literature on iron balance studies in patients with thalassaemia major show that the use of deferiprone concurrently with deferoxamine (co-administration of both chelators during the same day, either simultaneously or sequentially, e.g., deferiprone during the day and deferoxamine during the night), promotes greater iron excretion than either drug alone.
Estonian: Avaldatud andmed raua tasakaalu käsitlevatest uurimustest raske talasseemiaga patsientidel näitavad, et deferiprooni ja deferoksamiini samaaegne ravi (mõlema kelaativa aine samaaegne manustamine samal päeval, kas samaaegselt või järjestikuselt, nt deferiproon päevasel ajal ning deferoksamiin öösel), aitab kaasa suuremale raua väljutamisele kui kummagi ravimi kasutamine eraldi.
English: Deferiprone and deferoxamine were equivalent in promoting a net stabilization or reduction of body iron load, despite the continuous transfusional iron administration in those patients (no difference in proportion of patients with a negative trend in serum ferritin between the two treatment groups by regression analysis; p>0.05).
Estonian: Deferiproon ja deferoksamiin aitasid võrdselt soodustada organismi rauasisalduse stabiliseerimist või vähendamist, hoolimata neile patsientidele vereülekannetega pidevalt manustatavast rauakogusest (kahe ravigrupi vahel puudus regressioonianalüüsi põhjal erinevus vereseerumi negatiivse ferritiinitrendiga patsientide osakaalus; p > 0,05).
English: The safety of concurrent use of deferiprone and vitamin C has not been formally studied.
Estonian: Deferiprooni ja C-vitamiini samaaegse kasutamise ohutust ei ole uuritud.
English: Regardless of the degree of renal impairment, the majority of the dose of deferiprone was excreted in the urine over the first 24 hours as deferiprone 3-O-glucuronide.
Estonian: Sõltumata neerukahjustuse astmest eritus enamik deferiprooni annusest uriiniga esimese 24 tunni jooksul deferiprooni 3-O-glükuroniidina.
English: Based on the reported adverse interaction that can occur between deferoxamine and vitamin C, caution should be used when administering deferiprone and vitamin C concurrently.
Estonian: Tuginedes teatatud võimalikule ebasoodsale interaktsioonile deferoksamiini ja C-vitamiini vahel, on soovitatav olla ettevaatlik kasutades koos deferiprooni ja C-vitamiini.
English: In addition he or she might ask you to undergo liver biopsies.
Estonian: Lisaks võib ta paluda teil käia maksabiopsial.
English: PATIENT/CARER REMINDER CARD ((Front Cover))
Estonian: PATSIENDI/HOOLDAJA MEELESPEA-KAART ((Esikülg))
English: • To increase patient awareness of the significance of any symptoms of infection while taking Deferiprone Lipomed
Estonian: • suurendada patsientide teadlikkust mis tahes infektsioonisümptomite tähtsusest ravi ajal Deferiprone Lipomediga
English: Deferiprone Lipomed in combination with another chelator (see section 4.4) is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction (see section 4.2).
Estonian: Deferiprone Lipomed kombineerituna teise kelaativa ainega (vt lõik 4.4) on näidustatud raske talasseemiaga patsientidel, kui mistahes rauda kelaativ monoteraapia on ebapiisav või on vajalik kiire või intensiivne raua ülekoormuse eluohtlike tagajärgede ennetamine või ravi (vt lõik 4.2).
English: Monitoring your white blood cell count with Deferiprone Lipomed
Estonian: Teie vere valgeliblede arvu jälgimine Deferiprone Lipomedi kasutamise ajal
English: Do not take aluminium-based antacids at the same time as taking Deferiprone Lipomed.
Estonian: Ärge võtke alumiiniumipõhiseid antatsiide samaaegselt Deferiprone Lipomedi võtmisega.
English: If you experience nausea or vomiting, it may help to take your Deferiprone Lipomed with some food.
Estonian: Iivelduse või oksendamise puhul võib abiks olla Deferiprone Lipomedi tarvitamine koos toiduga.
English: Subjects were categorized into 3 groups based on the Child-Pugh classification score: healthy volunteers, mild hepatic impairment (Class A: 5- 6 points), and moderate hepatic impairment (Class B: 7- 9 points).
Estonian: Uuringus osalejad jagati kolme rühma vastavalt Childi-Pugh' klassifikatsiooni skoorile: terved vabatahtlikud, kerge maksakahjustus (klass A: 5…6 punkti) ja mõõdukas maksakahjustus (klass B: 7…9 punkti).
English: What you need to know before you take Deferiprone Lipomed
Estonian: Mida on vaja teada enne Deferiprone Lipomedi võtmist
English: Important Safety Reminders for Patients Taking Deferiprone Lipomed Prescribing doctor:________________________ Phone no:_______________________________
Estonian: Oluline ohutusalane meelespea Deferiprone Lipomedi kasutavatele patsientidele Raviarst:______________________________
English: The total daily dose should not exceed 100 mg/kg.
Estonian: Ööpäevane annus ei tohi ületada 100 mg/kg kehakaalu kohta.
English: Because white blood cells help to fight infection, a low neutrophil count may place you at risk of developing a serious and potentially life-threatening infection.
Estonian: Et vere valgelibled aitavad võidelda nakkusega, võib neutrofiilide väike arv tekitada tõsist ja potentsiaalselt eluohtlikku nakkuse tekkeriski.
English: The influence of severe hepatic impairment on the pharmacokinetics of deferiprone and deferiprone 3-O-glucuronide has not been evaluated.
Estonian: Raske maksakahjustuse mõju deferiprooni ja deferiprooni 3-O-glükuroniidi farmakokineetikale ei ole hinnatud.
English: In clinical trials, weekly monitoring of the neutrophil count has been effective in identifying cases of neutropenia and agranulocytosis and those episodes resolved once therapy was withdrawn.
Estonian: Kliinilistes uuringutes on iganädalane neutrofiilide hulga määramine osutunud efektiivseks meetodiks neutropeenia ja agranulotsütoosi juhtude avastamisel ning nende episoodid taandusid pärast deferiprooniga ravi katkestamist.
English: Study LA37-1111 was conducted to evaluate the effect of single therapeutic (33 mg/kg) and supratherapeutic (50 mg/kg) oral doses of deferiprone on the cardiac QT interval duration in healthy subjects.
Estonian: Uuring LA37-1111 korraldati eesmärgiga hinnata deferiprooni ühekordse terapeutilise (33 mg/kg) ja supraterapeutilise (50 mg/kg) suukaudse annuse mõju südame QT-intervalli pikkusele tervetel uuringus osalejatel.
English: Do not take Deferiprone Lipomed if you are pregnant or if you are trying to become pregnant.
Estonian: Ärge võtke Deferiprone Lipomedi, kui olete rase või soovite rasestuda.
English: To obtain a dose of about 75 mg/kg/day, use the number of tablets suggested in the following tables for the body weight of the patient.
Estonian: Ööpäevase annuse 75 mg/kg saavutamiseks kasutada soovitatud tablettide arvu sõltuvalt patsiendi kehakaalust.
English: Tablet core: hypromellose, croscarmellose sodium, silica, colloidal anhydrous, microcrystalline cellulose, magnesium stearate
Estonian: Tableti sisu: hüpromelloos, naatriumkroskarmelloos, kolloidne veevaba ränidioksiid, mikrokristalliline tselluloos, magneesiumstearaat
English: INFORMATION IN BRAILLE Deferiprone Lipomed 500 mg
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Deferiprone Lipomed 500 mg
English: The most common adverse reactions reported during therapy with deferiprone in clinical trials were nausea, vomiting, abdominal pain, and chromaturia, which were reported in more than 10% of patients.
Estonian: Deferiprooniga ravi kliinilistes uuringutes olid kõige levinumateks kõrvaltoimeteks iiveldus, oksendamine, kõhuvalu ning kromatuuria, mida täheldati rohkem kui 10% patsientidest.
English: After starting Deferiprone Lipomed therapy, it is recommended that serum ferritin concentrations, or other indicators of body iron load, be monitored every two to three months to assess the long-term effectiveness of the chelation regimen in controlling the body iron load.
Estonian: Pärast ravi alustamist Deferiprone Lipomediga on soovitatav jälgida iga kahekolme kuu tagant vereseerumi ferritiini kontsentratsiooni ja teisi organismi rauakoormuse näitajaid, et hinnata kelatsioonirežiimi tõhusust organismi rauakoormuse juhtimisel.
English: Instruct the patient to immediately discontinue deferiprone and all other medicinal products with a potential to cause neutropenia.
Estonian: Selgitage patsiendile, et ta kohe katkestaks deferiprooni ja potentsiaalselt neutropeeniat põhjustavate ravimite kasutamise.
English: The effect of Deferiprone Lipomed in decreasing the body iron is directly influenced by the dose and the degree of iron overload.
Estonian: Deferiprone Lipomedi organismi rauasisaldust vähendavat toimet mõjutab otseselt annuse suurus ning raua ülekoormuse määr.
English: This condition, known as severe neutropenia or agranulocytosis, has occurred in 1 to 2 out of 100 people who have taken deferiprone in clinical studies.
Estonian: See seisund, mida tuntakse raske neutropeenia või agranulotsütoosina, on esinenud 1…2 inimesel 100st, kes on võtnud kliiniliste uuringute ajal deferiprooni.
English: The most serious adverse reaction reported in clinical trials with deferiprone was agranulocytosis, defined as an absolute neutrophil count less than 0.5 x 109/l, which occurred in approximately 1% of patients.
Estonian: Kõige tõsisemateks kõrvaltoimeteks, millest teatati deferiprooniga ravi kliinilistes uuringutes, oli agranulotsütoos, mida määratleti neutrofiilide absoluutarvuna alla 0,5·109/l ja mida esines ligikaudu 1% patsientidest.
English: Interruption of therapy with deferiprone should be considered if serum ferritin falls below 500 µg/l.
Estonian: Deferiprooniga ravi katkestamist tuleb kaaluda juhul, kui vereseerumi ferritiin langeb alla 500 µg/l.
English: If the patient develops an infection while on deferiprone, therapy should be interrupted and the neutrophil count monitored more frequently.
Estonian: Kui ravi ajal deferiprooniga lisandub mõni infektsioonhaigus, tuleb ravi samuti katkestada ja neutrofiilide hulka sagedamini kontrollida.
English: Deferiprone Lipomed is used to treat iron overload caused by frequent blood transfusions in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.
Estonian: Deferiprone Lipomedi kasutakse raua ülekoormuse raviks, mille on põhjustanud sagedased vereülekanded raske talasseemiaga patsientidel, kui praegune kelaativ ravi on vastunäidustatud või ebapiisav.
English: Deferiprone is metabolised predominantly to a glucuronide conjugate.
Estonian: Deferiproon metaboliseerub peamiselt glükuroniidkonjugaatideks.
English: Abdominal pain Vomiting
Estonian: Iiveldus Kõhuvalu Oksendamine
English: The higher rate of “Cardiac disorders” reported during combination therapy than monotherapy was possibly due to the higher incidence of pre-existing cardiac disorders in patients who received combination therapy.
Estonian: Kombinatsioonravi ajal monoteraapiast suurem „Südame häired“ esinemise sagedus oli võimalik tulenevalt suuremast esinemisest eelnevalt südamehäiretest kombinatsioonravi saanud patsientidel.
English: Deferiprone use should be discontinued if neurological disorders are observed (see sections 4.8 and 4.9).
Estonian: Deferiprooni kasutamine tuleb neuroloogiliste häirete ilmnemisel lõpetada (vt lõigud 4.8 ja
English: If you take more Deferiprone Lipomed than you should There are no reports of acute overdose with deferiprone.
Estonian: Kui võtate Deferiprone Lipomedi rohkem kui ette nähtud Deferiprone Lipomedi kasutamisel ei ole teatatud ägedast üleannustamisest.
English: Phone number: +49 7621 1693 472 Fax number: +49 7621 1693 474 Electronic mail: lipomed@lipomed.com
Estonian: Telefon: +49 7621 1693 472 Faks: +49 7621 1693 474 E-post: lipomed@lipomed.com
English: Deferiprone AUCs did not differ between treatment groups, but Cmax was decreased by 20% in mildly or moderately hepatically impaired subjects compared with healthy volunteers.
Estonian: Deferiprooni AUC-d ei erinenud ravigruppide lõikes, kuid Cmax vähenes kerge või mõõduka maksakahjustusega patsientidel 20% võrreldes tervete vabatahtlikega.
English: Peak serum concentrations of the glucuronide occur 2 to 3 hours after administration of deferiprone.
Estonian: Glükuroniidi maksimaalne kontsentratsioon seerumis saabub 2 kuni 3 tundi pärast deferiprooni manustamist.
English: One pack contains 100 film-coated tablets.
Estonian: Ühes pakendis on 100 õhukese polümeerikattega tabletti.
English: 79576 Weil am Rhein Germany
Estonian: 79576 Weil am Rhein Saksamaa
English: Phone number: +49 7621 1693 472 Fax number: +49 7621 1693 474 lipomed@lipomed.com
Estonian: Telefon: +49 7621 1693 472 Faks: +49 7621 1693 474 lipomed@lipomed.com
English: Prescribers are reminded that the use of doses above 100 mg/kg/day is not recommended.
Estonian: Annuse määramisel tuleb meeles pidada, et 100 mg/kg/ööpäevas ületavate annuste kasutamine ei ole soovitatav.
English: The risk of agranulocytosis and neutropenia is higher if the baseline absolute neutrophil count (ANC) is less than 1.5 x 109/l.
Estonian: Agranulotsütoosi ja neutropeenia risk on suurem, kui neutrofiilsete leukotsüütide absoluutarv ravi alguses on väiksem kui 1,5·109/l.
English: Deferiprone-3-O-glucuronide AUC was decreased by 10% and Cmax by 20% in mildly and moderately impaired subjects compared with healthy volunteers.
Estonian: Deferiprooni 3-O-glükuroniidi AUC vähenes kerget ja mõõduka kahjustusega patsientidel 10% ja Cmax 20% võrra võrreldes tervete vabatahtlikega.
English: Please refer to the patient/carer reminder card provided in the folding box.
Estonian: Palun juhtige patsiendi/hooldaja tähelepanu meelespea-kaardile karbis.
English: The most serious side effect that may occur while taking Deferiprone Lipomed is a very low white blood cell (neutrophil) count.
Estonian: Kõige raskem kõrvaltoime, mis võib tekkida Deferiprone Lipomedi võtmise ajal, on vere valgeliblede (neutrofiilide) väga väike arv.
English: The amount of Deferiprone Lipomed that you take will depend on your weight.
Estonian: Teile vajalik Deferiprone Lipomedi annus sõltub teie kehakaalust.
English: Deferiprone Lipomed is an iron chelator, a type of medicine that removes excess iron from the body.
Estonian: Deferiprone Lipomed on raua kelaatija, mis eemaldab organismist liigse raua.
English: There is a small chance that you may develop agranulocytosis (very low white blood cell count) while taking Deferiprone Lipomed, which may lead to a serious infection.
Estonian: On väike võimalus, et Deferiprone Lipomedi kasutamise ajal tekib teil agranulotsütoos (teatud tüüpi vere valgeliblede väga väike arv), mille tulemusena võib tekkida raske infektsioon (nakkus).
English: The observed incidence of the less severe form of neutropenia (neutrophils <1.5 x 109/l) is 4.9% (2.5 cases per 100 patient-years).
Estonian: Neutropeenia kergemate, leukopeeniana klassifitseeritud juhtude (neutrofiile <1,5·109/l) oli 4,9% (2,5 juhtu 100 patsiendiaasta kohta).
English: In humans, deferiprone is eliminated mainly via the kidneys; 75% to 90% of the ingested dose is reported as being recovered in the urine in the first 24 hours, in the form of free deferiprone, the glucuronide metabolite and the iron-deferiprone complex.
Estonian: 75 kuni 90% manustatud annusest eritub uriiniga esimese 24 tunni jooksul vaba deferiprooni, glükuroniidmetaboliitide ja raud-deferiproonkompleksidena.
English: • Due to the unknown mechanism of deferiprone-induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 4.5).
Estonian: • Kuna deferiprooni kasutamisest põhjustatud neutropeenia mehhanism ei ole teada, ei tohi patsiendid kasutada neutropeeniaga seostatavaid ravimeid või ravimeid, mis võivad põhjustada agranulotsütoosi (vt lõik 4.5).
English: NAME OF THE MARKETING AUTHORISATION HOLDER Lipomed GmbH
Estonian: MÜÜGILOA HOIDJA NIMI Lipomed GmbH
English: The most serious adverse reaction reported in clinical trials with deferiprone is agranulocytosis (neutrophils <0.5 x 109/l), with an incidence of 1.1% (0.6 cases per 100 patient-years of treatment) (see section 4.4).
Estonian: Kliinilistes uuringutes ilmnenud tõsiseim negatiivne deferiprooni kõrvaltoime on agranulotsütoos (neutrofiile <0,5·109/l), mille esinemissagedus on 1,1% (0,6 juhtu 100 ravitud patsiendi kohta aastas (vt lõik 4.4).
English: Peak serum concentration occurs 45 to 60 minutes following a single dose in fasted patients.
Estonian: Ravimi maksimaalne kontsentratsioon seerumis saabub tühja kõhu korral 45 kuni 60 minutit pärast ühekordse annuse manustamist.
English: There are no data available on the use of deferiprone in patients with end stage renal disease or severe hepatic impairment (see section 5.2).
Estonian: Andmed deferiprooni kasutamise kohta lõppstaadiumis neeru- või raske maksakahjustusega patsientidel puuduvad (vt lõik 5.2).
English: The neurological disorders progressively regressed after deferiprone discontinuation (see sections 4.4 and 4.9).
Estonian: Pärast deferiprooni manustamise katkestamist need sümptomid järk-järgult taandusid (vt lõigud 4.4 ja 4.9).
English: The incidences of “Musculoskeletal and connective tissue disorders” and “Renal and urinary disorders” were lower during combination therapy than monotherapy, whereas the incidence of “Cardiac disorders” was higher during combination therapy than monotherapy.
Estonian: Esinemine oli harvem jaotistes „Lihas-skeleti ja sidekoe kahjustused“ ning „Neerude ja kuseteede häired“ kombinatsioonravi puhul võrreldes monoteraapiaga, samal ajal kui jaotises „Südame häired“ oli esinemine sagedam kombinatsioonravi puhul võrreldes monoteraapiaga.
English: What Deferiprone Lipomed looks like and contents of the pack Deferiprone Lipomed 500 mg film-coated tablets are white to off-white, glossy surface, oval filmcoated tablets.
Estonian: Kuidas Deferiprone Lipomed välja näeb ja pakendi sisu Deferiprone Lipomedi 500 mg õhukese läikiva polümeerikattega ovaalsed tabletid on valged või peaaegu valged.
English: Based on the results of this study, no adjustment of the deferiprone dosage regimen is required in patients with impaired renal function.
Estonian: Selle uuringu tulemuste põhjal ei ole neerufunktsiooni kahjustusega patsientidel vaja deferiprooni annustamisskeemi korrigeerida.
English: Dose adjustment
Estonian: Annustamise kohandamine
English: Aluminium/PVC-PVDC blisters in cartons of 100 film-coated tablets.
Estonian: 100 õhukese polümeerikattega tabletti alumiinium-/PVC-PVDC-blisterpakendis.
English: Dose per kilogram body weight should be calculated to the nearest half tablet.
Estonian: Annus kehakaalu kohta tuleb arvutada poole tableti täpsusega.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 500 mg deferiprone.
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Üks õhukese polümeerikattega tablett sisaldab 500 mg deferiprooni.
English: - Provided in the folding box, you will find a patient/carer reminder card. You should complete and read the card carefully and carry it with you.
Estonian: Kaart tuleb täita ja lugeda tähelepanelikult ja kanda endaga kaasas.
English: Deferiprone is usually given as 25 mg/kg body weight, orally, three times a day for a total daily dose of 75 mg/kg body weight.
Estonian: Deferiprooni manustatakse suu kaudu tavaliselt annuses 25 mg kehakaalu kg kohta (mg/kg) kolm korda ööpäevas; ööpäevane koguannus on 75 mg/kg.
English: Neurological disorders have been observed in children treated with more than 2.5 times the maximum recommended dose for several years but have also been observed with standard doses of deferiprone.
Estonian: Krooniline üleannustamine ja neuroloogilised häired Neuroloogilisi häireid on täheldatud lastel, kellele mitme aasta jooksul määrati üle 2,5 korra maksimaalset soovitatavat annust ületav annus, aga ka deferiprooni standardannuste puhul.
English: There are limited data available on the use of deferiprone in children between 6 and 10 years of age, and no data on deferiprone use in children under 6 years of age.
Estonian: Alla 6aastaste laste kohta vastavad andmed puuduvad.
English: Careful monitoring of cardiac events in patients on combination therapy is warranted (see section 4.4).
Estonian: Õigustatud on kombinatsioonravi saavate patsientide tähelepanelik jälgimine, kui neil esineb südametöö häireid (vt lõik 4.4).
English: Each 500 mg film-coated tablet contains 500 mg deferiprone.
Estonian: Üks 500 mg õhukese polümeerikattega tablett sisaldab 500 mg deferiprooni.
English: No effects on fertility or early embryonic development were noted in non-iron-loaded male and female rats that received deferiprone orally at doses of up to 75 mg/kg twice daily for 28 days (males) or 2 weeks (females) prior to mating and until termination (males) or through early gestation (females).
Estonian: Raua ülekoormuseta isastel ja emastel rottidel, kellele manustati deferiprooni oraalsel teel annustena kuni 75 mg/kg kaks korda ööpäevas 28 päeva jooksul (isased (või 2 nädala jooksul (emased) enne paaritumist ja kuni surmamiseni (isased) või varase tiinuse ajal (emased), ei täheldatud mingeid mõjusid fertiilsusele ega varasele lootearengule.
English: What Deferiprone Lipomed is and what it is used for 2.
Estonian: Mis ravim on Deferiprone Lipomed ja milleks seda kasutatakse
English: Provide protective isolation and if clinically indicated, admit patient to the hospital.
Estonian: Patsient isoleerida ja kliinilise näidustuse olemasolul hospitaliseerida.
English: An open-label, non-randomized, parallel group clinical study was conducted to evaluate the effect of impaired renal function on the safety, tolerability, and pharmacokinetics of a single 33 mg/kg oral dose of deferiprone.
Estonian: Avatud, randomiseerimata, paralleelrühmadega kliiniline uuring viidi läbi, et hinnata neerufunktsiooni kahjustuse mõju deferiprooni ühekordse 33 mg/kg suukaudse annuse ohutusele, taluvusele ja farmakokineetikale.
English: Patients should be advised to report immediately to their physician any symptoms indicative of infection such as fever, sore throat or flu-like symptoms.
Estonian: Patsiente tuleb teavitada vajadusest kohe informeerida oma raviarsti kõigist infektsioonhaigusele viitavatest nähtudest nagu palavik, kurguvalu või gripile iseloomulikud sümptomid.
English: The most serious side effect of Deferiprone Lipomed is a very low white blood cell (neutrophil) count.
Estonian: Kõige tõsisemaks Deferiprone Lipomedi kõrvaltoimeks on vere valgeliblede (neutrofiilide) arvu vähenemine väga madalale tasemele.
English: Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.
Estonian: Deferiprone Lipomed monoteraapia on näidustatud raua ülekoormuse korral raske talasseemiaga patsientidel, kui praegune kelaativ ravi on vastunäidustatud või ebapiisav.
English: Clinical studies have demonstrated that deferiprone is effective in promoting iron excretion and that a dose of 25 mg/kg three times per day can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with transfusion-dependent thalassaemia.
Estonian: Kliinilised uuringud on näidanud, et deferiproon soodustab efektiivselt raua ekskretsiooni ning väldib annuses 25 mg/kg 3 korda ööpäevas raua akumulatsiooni.
English: Do not use Deferiprone Lipomed if you are breast-feeding.
Estonian: Ärge kasutage Deferiprone Lipomedi rinnaga toitmise ajal.
English: Should any evidence of infection develop concurrently with the neutropenia, the appropriate cultures and diagnostic procedures should be performed and an appropriate therapeutic regimen instituted.
Estonian: Kui koos neutropeeniaga esineb ka infektsiooninähte, tuleb teha analüüsid tekitaja määramiseks, diagnostilised uuringud ja määrata ravi.
English: Deferiprone has been shown to cause neutropenia, including agranulocytosis.
Estonian: On tõestatud, et deferiproon põhjustab neutropeeniat ja agranulotsütoosi.